Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib
06-Jun-2022 -
Repare Therapeutics Inc. announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related ...
cancer
oncology
small molecule inhibitors